Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R-/-) mice

Vascular Pharmacology

Volumn 57, Issue 1, 2012, Pages 56-64

  Poti, Francesco ^a   Costa, Sara ^a   Bergonzini, Valeria ^a   Galletti, Margherita ^a   Pignatti, Elisa ^a   Weber, Christian ^b   Simoni, Manuela ^a   Nofer, Jerzy Roch ^a,c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Atherosclerosis; High density lipoproteins (HDL); Inflammation; Sphingosine 1 phosphate (S1P)

Indexed keywords

CD11B ANTIGEN; CHLORDANE; CYM 5442; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; HYPERCHOLESTEROLEMIA; LYMPH NODE; LYMPHOCYTE; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD11B; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ATHEROSCLEROSIS; BODY WEIGHT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENES, MHC CLASS II; INDANS; INTERLEUKIN-2; INTERLEUKIN-6; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED C57BL; OXADIAZOLES; PROPROTEIN CONVERTASES; PROPYLENE GLYCOLS; RECEPTORS, LDL; RECEPTORS, LYSOSPHINGOLIPID; SERINE ENDOPEPTIDASES; SPHINGOSINE; SPLEEN;

EID: 84862509411     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.03.003     Document Type: Article

References (42)

1. Awad A.S., Rouse M.D., Khutsishvili K., Huang L., Bolton W.K., Lynch K.R., Okusa M.D. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int. 2011, 79:1090-1098.
2. Bajwa A., Jo S.K., Ye H., Huang L., Dondeti K.R., Rosin D.L., Haase V.H., Macdonald T.L., Lynch K.R., Okusa M.D. Activation of sphingosine-1-phosphate 1 receptor in the proximal tubule protects against ischemia-reperfusion injury. J. Am. Soc. Nephrol. 2010, 21:955-965.
3. Berdyshev E.V., Gorshkova I., Skobeleva A., Bittman R., Lu X., Dudek S.M., Mirzapoiazova T., Garcia J.G., Natarajan V. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J. Biol. Chem. 2009, 284:5467-5477.
4. Blom T., Bäck N., Mutka A.L., Bittman R., Li Z., de Lera A., Kovanen P.T., Diczfalusy U., Ikonen E. FTY720 stimulates 27-hydroxycholesterol production and confers atheroprotective effects in human primary macrophages. Circ. Res. 2010, 106:720-729.
5. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., Aradhye S., Burtin P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 2010, 9:883-897.
6. Buono C., Come C.E., Stavrakis G., Maguire G.F., Connelly P.W., Lichtman A.H. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 2003, 23:454-460.
7. Christoffersen C., Obinata H., Kumaraswamy S.B., Galvani S., Ahnström J., Sevvana M., Egerer-Sieber C., Muller Y.A., Hla T., Nielsen L.B., Dahlbäck B. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:9613-9618.
8. Cinti S. Transdifferentiation properties of adipocytes in the adipose organ. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E977-E986.
9. Corrado E., Rizzo M., Coppola G., Fattouch K., Novo G., Marturana I., Ferrara F., Novo S. An update on the role of markers of inflammation in atherosclerosis. J. Atheroscler. Thromb. 2010, 17:1-11.
10. Daugherty A., Whitman S.C. Quantification of atherosclerosis in mice. Methods Mol. Biol. 2003, 209:293-309.
11. Getz G.S. Diet and murine atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:242-249.
12. Gonzalez-Cabrera P.J., Jo E., Sanna M.G., Brown S., Leaf N., Marsolais D., Schaeffer M.T., Chapman J., Cameron M., Guerrero M., Roberts E., Rosen H. Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol. Pharmacol. 2008, 74:1308-1318.
13. Gosling J., Slaymaker S., Gu L., Tseng S., Zlot C.H., Young S.G., Rollins B.J., Charo I.F. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 1999, 103:773-778.
14. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
15. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 2006, 6:508-519.
16. Hojjati M.R., Li Z., Zhou H., Tang S., Huan C., Ooi E., Lu S., Jiang X.C. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J. Biol. Chem. 2005, 280:10284-10289.
17. Jo E., Sanna M.G., Gonzalez-Cabrera P.J., Thangada S., Tigyi G., Osborne D.A., Hla T., Parrill A.L., Rosen H. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem. Biol. 2005, 12:703-715.
18. Kendall M.R., Hupfeld C.J. FTY720, a sphingosine-1-phosphate receptor modulator, reverses high-fat diet-induced weight gain, insulin resistance and adipose tissue inflammation in C57BL/6 mice. Diabetes Obes. Metab. 2008, 10:802-805.
19. Keul P., Tölle M., Lucke S., von Wnuck Lipinski K., Heusch G., Schuchardt M., van der Giet M., Levkau B. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:607-613.
20. Keul P., Lucke S., von Wnuck Lipinski K., Bode C., Gräler M., Heusch G., Levkau B. Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ. Res. 2011, 108:314-323.
21. Kleemann R., Verschuren L., van Erk M.J., Nikolsky Y., Cnubben N.H., Verheij E.R., Smilde A.K., Hendriks H.F., Zadelaar S., Smith G.J., Kaznacheev V., Nikolskaya T., Melnikov A., Hurt-Camejo E., van der Greef J., van Ommen B., Kooistra T. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol. 2007, 8:R200.
22. Klingenberg R., Nofer J.R., Rudling M., Bea F., Blessing E., Preusch M., Grone H.J., Katus H.A., Hansson G.K., Dengler T.J. Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2392-2399.
23. Koenen R.R., von Hundelshausen P., Nesmelova I.V., Zernecke A., Liehn E.A., Sarabi A., Kramp B.K., Piccinini A.M., Paludan S.R., Kowalska M.A., Kungl A.J., Hackeng T.M., Mayo K.H., Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 2009, 15:97-103.
24. Kontush A., Therond P., Zerrad A., Couturier M., Négre-Salvayre A., de Souza J.A., Chantepie S., Chapman M.J. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1843-1849.
25. Murphy A.J., Woollard K.J. High-density lipoprotein: a potent inhibitor of inflammation. Clin. Exp. Pharmacol. Physiol. 2010, 37:710-718.
26. Nofer J.R. High-density lipoprotein, sphingosine 1-phosphate, and atherosclerosis. J. Clin. Lipidol. 2008, 2:4-11.
27. Nofer J.R., Assmann G. Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc. Med. 2005, 15:265-271.
28. Nofer J.R., Bot M., Brodde M., Taylor P.J., Salm P., Brinkmann V., van Berkel T., Assmann G., Biessen E.A. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007, 115:501-508.
29. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
30. Sarwar N., Thompson A.J., Di Angelantonio E. Markers of inflammation and risk of coronary heart disease. Dis. Markers 2009, 26:217-225.
31. Sawicka E., Zuany-Amorim C., Manlius C., Trifilieff A., Brinkmann V., Kemeny D.M., Walker C. Inhibition of Th1- and Th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. J. Immunol. 2003, 171:6206-6214.
32. Skoura A., Michaud J., Im D.S., Thangada S., Xiong Y., Smith J.D., Hla T. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011, 31:81-85.
33. Stokes K.Y., Clanton E.C., Russell J.M., Ross C.R., Granger D.N. NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circ. Res. 2001, 88:499-505.
34. Stokes K.Y., Clanton E.C., Clements K.P., Granger D.N. Role of interferon-gamma in hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circulation 2003, 107:2140-2145.
35. Stokes K.Y., Clanton E.C., Gehrig J.L., Granger D.N. Role of interleukin 12 in hypercholesterolemia-induced inflammation. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H2623-H2629.
36. Subramanian S., Han C.Y., Chiba T., McMillen T.S., Wang S.A., Haw A., Kirk E.A., O'Brien K.D., Chait A. Dietary cholesterol worsens adipose tissue macrophage accumulation and atherosclerosis in obese LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:685-691.
37. Swirski F.K., Libby P., Aikawa E., Alcaide P., Luscinskas F.W., Weissleder R., Pittet M.J. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 2007, 117:195-205.
38. Tabet F., Rye K.A. High-density lipoproteins, inflammation and oxidative stress. Clin. Sci. (Lond.) 2009, 116:87-98.
39. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
40. Wielinga P.Y., Yakala G.K., Heeringa P., Kleemann R., Kooistra T. Beneficial effects of alternate dietary regimen on liver inflammation, atherosclerosis and renal activation. PLoS One 2011, 6:e18432.
41. Wolf A.M., Eller K., Zeiser R., Dürr C., Gerlach U.V., Sixt M., Markut L., Gastl G., Rosenkranz A.R., Wolf D. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J. Immunol. 2009, 183:3751-3760.
42. Zhang B., Tomura H., Kuwabara A., Kimura T., Miura S., Noda K., Okajima F., Saku K. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 2005, 178:199-205.